Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Athenex sells revenues from US, European royalty, milestone interest in Klisyri » 08:35
06/22/22
06/22
08:35
06/22/22
08:35
ATNX

Athenex

/

+

Athenex announced the…

Athenex announced the signing of a definitive agreement for the sale of revenues from U.S. and European royalty and milestone interests in Klisyri to Sagard Healthcare Partners and funds managed by Oaktree Capital Management for $85M. Approximately $80M of the proceeds from the transaction will be used toward partially paying down existing debt and operating the business, with $5M to be placed into escrow and paid to Athenex upon the satisfaction of certain conditions. The transaction is subject to customary closing conditions. "We are executing on our new strategy and will continue to deliver on the objectives that we laid out to extend our cash runway by over 18 months. We are pleased to enter into this agreement, as we believe it generates meaningful benefits for our stockholders as we continue to pay down debt and extend our cash runway," said Dr. Johnson Lau, Chief Executive Officer of Athenex. "The sale of the revenues from the U.S. and European royalty and milestone interests in Klisyri represents another step in continuing to monetize non-core assets to focus on developing our potential best-in-class NKT cell platform."

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

ATNX Athenex
/

+

Hot Stocks
Athenex appoints Darrel Cohen as CMO, cell therapy » 08:26
06/08/22
06/08
08:26
06/08/22
08:26
ATNX

Athenex

/

+

Athenex announced the…

Athenex announced the appointment of Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to lead its clinical development, clinical operations, and regulatory affairs functions. He will be replacing Kurt Gunter, MD, who has decided to pursue other opportunities outside of cell therapy. Most recently, Dr. Cohen was Head of Clinical Development at EUSA Pharma then Chief Medical Officer at Biosight Pharmaceuticals, having been a principal investigator on several clinical trials in the past and co-authored numerous peer-reviewed publications.

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

ATNX Athenex
/

+

Over a month ago
Conference/Events
Athenex management to meet with Oppenheimer » 04:55
05/20/22
05/20
04:55
05/20/22
04:55
ATNX

Athenex

/

+

Meeting to be held in New…

Meeting to be held in New York on May 20 hosted by Oppenheimer.

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

ATNX Athenex
/

+

Hot Stocks
Athenex announces clinical collaboration with Merck to evaluate oraxol » 08:45
05/16/22
05/16
08:45
05/16/22
08:45
ATNX

Athenex

/

+

, MRK

Merck

$90.42 /

-0.41 (-0.45%)

Athenex (ATNX) announced…

Athenex (ATNX) announced a clinical trial collaboration and supply agreement with Merck (MRK). The agreement applies to the expansion phase of the Phase 1 clinical trial evaluating Athenex's oral paclitaxel in combination with Merck's anti-PD-1 therapy KEYTRUDA for certain NSCLC patients. The agreement will support the expansion phase of the trial to further investigate the preliminary encouraging results of the KX-ORAX-011 Phase 1 clinical trial evaluating Oraxol in combination with pembrolizumab for certain NSCLC patients. The two companies will form a Joint Development Committee to review the clinical trial results. "We are keen to collaborate with Merck to further investigate the therapeutic potential of Oraxol plus KEYTRUDA in patients with NSCLC patients who progressed on previous anti-PD1/ anti-PD-L1 therapy or in combination with chemotherapy," said Dr. Rudolf Kwan, Chief Medical Officer of Athenex. "If the preliminary efficacy and safety data can be confirmed, it may lead to a new paradigm in the treatment of certain NSCLC patients."

ShowHide Related Items >><<
MRK Merck
$90.42 /

-0.41 (-0.45%)

ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
MRK Merck
$90.42 /

-0.41 (-0.45%)

04/12/22 Barclays
Merck price target raised to $97 from $94 at Barclays
04/11/22 H.C. Wainwright
Rubius Therapeutics price target lowered to $15 from $40 at H.C. Wainwright
04/06/22 Morgan Stanley
Merck assumed with an Equal Weight at Morgan Stanley
04/05/22 BMO Capital
Merck targets 'ambitious' $10B revenue from cardiovascular franchise, says BMO
MRK Merck
$90.42 /

-0.41 (-0.45%)

ATNX Athenex
/

+

MRK Merck
$90.42 /

-0.41 (-0.45%)

MRK Merck
$90.42 /

-0.41 (-0.45%)

ATNX Athenex
/

+

MRK Merck
$90.42 /

-0.41 (-0.45%)

Conference/Events
Athenex management to meet with Oppenheimer » 16:56
05/12/22
05/12
16:56
05/12/22
16:56
ATNX

Athenex

/

+

Meeting to be held on May…

Meeting to be held on May 20 hosted by Oppenheimer.

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

ATNX Athenex
/

+

Hot Stocks
Athenex plans to extend cash runway into 2023 » 07:22
05/10/22
05/10
07:22
05/10/22
07:22
ATNX

Athenex

/

+

As of March 31, 2022, the…

As of March 31, 2022, the company had cash and cash equivalents of $27.2 million, restricted cash of $13.8 million, and short-term investments of $10.2 million, for a total of $51.2 million. The company is implementing cost savings programs and monetizing non-core assets, and as the company completes such activities, the company plans to extend its cash runway into next year.

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

ATNX Athenex
/

+

Hot Stocks
Athenex sees FY22 product sales growth 20%-25% vs. prior range of 15%-20% » 07:22
05/10/22
05/10
07:22
05/10/22
07:22
ATNX

Athenex

/

+

Athenex now expects…

Athenex now expects product sales growth to be in the range of 20-25% over the prior year period, versus the prior range of 15-20% growth, year-over-year, due to the strong performance of Athenex's APD/APS division, earlier than expected NY State license, and the robust pipeline of launches planned for the remainder of 2022.

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

ATNX Athenex
/

+

Earnings
Athenex reports Q1 EPS (16c), consensus (19c) » 07:21
05/10/22
05/10
07:21
05/10/22
07:21
ATNX

Athenex

/

+

Reports Q1 revenue…

Reports Q1 revenue $29.7M, consensus $25.42M. "Our focus for 2022 continues to be on transforming Athenex into a robust, well-positioned cell therapy company with a solid balance sheet. We are proud of the progress we have made since announcing our strategic pivot and remain committed to delivering on cutting operating expenses and executing on additional monetization of noncore assets," said Johnson Lau, Chief Executive Officer of Athenex. "Our cell therapy programs continue to generate exciting data, which we are looking forward to presenting throughout the year. We believe our NKT cell therapy platform will be the main driver of future growth and will position us to be a differentiated leader in cell therapy space. Our corporate initiatives continue to set us up for successful value creation and allow us to further execute on our ultimate mission of bringing innovative treatments to cancer patients."

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

Conference/Events
Athenex management to meet virtually with Oppenheimer » 05:55
04/26/22
04/26
05:55
04/26/22
05:55
ATNX

Athenex

/

+

Virtual Meetings to be…

Virtual Meetings to be held on April 25-26 hosted by Oppenheimer.

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

ATNX Athenex
/

+

Hot Stocks
Athenex presents interim data from ANCHOR Phase 1 study of KUR-502 » 08:21
04/25/22
04/25
08:21
04/25/22
08:21
ATNX

Athenex

/

+

Athenex announced data…

Athenex announced data from the ANCHOR Phase 1 study of KUR-502 during an oral presentation by Carlos Ramos, M.D., professor, Center for Cell and Gene Therapy, Baylor College of Medicine, at the Tandem Meetings of the American Society of Transplantation and Cellular Therapy, ASTCT, and the Center for International Blood & Marrow Transplant Research, CIBMTR, taking place April 23 to 26, in Salt Lake City, UT. "Encouraging data from the interim update of the ANCHOR study further support the promising efficacy and favorable safety profile of KUR-502 in heavily pretreated patients with hematological malignancies," said Dan Lang, M.D., President of Athenex Cell Therapy. "It is exciting to see the therapeutic benefit of our CAR-NKT cell therapy persists as the ANCHOR study matures, particularly in patients who have already progressed on autologous CAR-T therapy. We intend to collect additional patient data as we expand the study to include more sites and look forward to providing another update later this year." Highlights from the interim update include response data from seven evaluable patients, including two additional patients who were previously too early to assess: One patient with NHL had stable disease, and a second patient with ALL had progressive disease at the 4-week assessment; Two CRs persisted for more than 6 months with one at 34 weeks and still ongoing; Two responses were observed in patients who had relapsed after previous autologous CAR-T therapy; Excellent safety with no immune effector cell-associated neurotoxicity syndrome and no graft versus host disease attributable to CAR-NKT cells; Grade 1 cytokine release syndrome in 2 ALL patients.

ShowHide Related Items >><<
ATNX Athenex
/

+

ATNX Athenex
/

+

10/12/21 RBC Capital
Athenex price target lowered to $5 from $8 at RBC Capital
ATNX Athenex
/

+

ATNX Athenex
/

+

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.